LIGAND PHARMACEUTICALS INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121
Mailing Address 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121
Phone 858-550-7500
Fiscal Year End 1231
EIN 770160744
Financial Overview
FY2024
$52.15M
Net Income
$821.16M
Stockholders' Equity
$72.31M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 9, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
Insider Trading
STRONG SELL 2 insiders
18 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.